elvistudio

MAPS (Multidisciplinary Association for Psychedelic Studies) сообщает, что...

First LSD-Assisted Psychotherapy Study Begins!
The first subject was treated in Peter Gasser, MD’s LSD/end-of-life anxiety study in Switzerland on May 13th. This marks the beginning of what will become the first LSD-assisted psychotherapy study in over 36 years. While we’re sad that Albert Hofmann didn’t live to actually see the first administration of LSD in this study, we’re glad he knew the study was fully approved and that the initial subject was going to be enrolled in the study soon.

New Psilocybin Neurogenesis Study Begins at the University of South Florida
Researchers Juan Sanchez-Ramos PhD, MD and Briony Catlow MS at the University of South Florida in Tampa have just started an exciting new study to see if psilocybin can help promote the birth and development of new brain cells (neurogenesis) in an area of the adult brain called the hippocampus, which is associated with learning and memory. The psilocybin that is being used in this study is coming from an unused portion of a gram of psilocybin that MAPS purchased several years ago for $12,250 and then donated to the University of Arizona for Dr. Francisco Moreno’s psilocybin/OCD study.

Breakthrough PTSD Treatment Study with MDMA Nears Completion
Michael Mithoefer MD’s US MDMA/PTSD study is almost complete! In a few days, subjects #18, #19 and #20 will complete their final non-drug psychotherapy sessions. For final outcome measures, one will be completed later in June and another one in early July. Subject #21 will have her third MDMA session in July, and her final outcome measures in September. After that the study will be finished and we’ll analyze the data. Then we’ll prepare a report to the FDA and write a scientific article for submission to a peer-reviewed journal for publication. There are many steps in our march toward Phase 3 trials. However, with the completion of this initial pilot study--which will become the foundation on which everything else will be built--eventually, the prescription use of MDMA for PTSD will be available for all who need it. A breakthrough treatment for PTSD is sorely needed…and with your help, we will give this gift of healing to the world.

Boom Festival Seeks PsyEMS Volunteers

The Boom Festival in Portugal is now accepting applications for volunteers to provide Psychedelic Emergency Services. If you are interested in getting involved and can pay for your own travel expenses to the festival, please contact David at: kosmicare @ boomfestival org

Final Approval for MAPS-Sponsored Swiss LSD/End-of-Life Anxiety Study
On December 5, Dr. Peter Gasser received the final permission for his MAPS-sponsored LSD/end-of-life anxiety study! He had previously received approval from Swissmedic (Swiss FDA) and a Swiss Ethics Committee (see this letter). This approval marks the completion of the initial phase of the psychedelic research renaissance, which has been building slowly since 1990.

Scientific American Mind Magazine Feature Article on Research With Psychedelics
The December/January issue of Scientific American Mind magazine features my article "Psychedelic Healing?,” (PDF format) which summarizes much of the research into psychedelics that has gone on in recent years. In the article I discuss how MDMA, psilocybin, LSD, ibogaine and other psychedelics are being studied as treatments for posttraumatic stress disorder, obsessive-compulsive disorder, cluster headaches, anxiety associated with cancer, drug addiction, and other difficult-to-treat psychiatric disorders. I also discuss the neurochemistry of how psychedelics affect the brain.

New Paper Published on Holotropic Breathwork
Joseph P.Rhinewine and Oliver J. Williams recently published an excellent paper on holotropic breathwork-- in The Journal of Alternative and Complementary Medicine titled “Holotropic Breathwork: The Potential Role of a Prolonged, Voluntary Hyperventilation Procedure as an Adjunct to Psychotherapy.” The paper makes a strong case for holotropic breathwork research.

DEA Allows Hemp to be grown at North Dakota State University
The DEA is permitting hemp to be grown for research at North Dakota State University. This permission was granted by the DEA after sitting on the application for eight years. The DEA rejected an application for a larger commercial production project in North Dakota, and a federal court just ruled against the farmers who sued the DEA. The approval of the license for NDSU demonstrates that the DEA does sometimes feel forced to move off of in action and delay to giving licenses that it prefers not to give. We hope this is a precedent that will be repeated in Prof. Craker’s case against the DEA, seeking a license for aprivately-funded medical marijuana production facility in the U.S.-- a casewhich we won in court but has yet to be implemented by the DEA. See this press release for more details.

New Israeli Therapist Team Came to Train with the Mithoefers for MDMA PTSD Study
Two Israeli co-therapists in MAPS’ Israeli MDMA/PTSD study, Sergio Marchevsky, M.D. and Marina Kupcheck M.D., were in Charleston, South Carolina from Friday, December 7 to Sunday, December 9, to monitor an MDMA PTSD session conducted by Michael Mithoefer M.D. and Annie Mithoefer, R.N.. Observing an MDMA/PTSD session is part of their training prior to enrolling the first subjects in the Israeli MDMA PTSD study. MAPS is developing a therapist training protocol that we intend to submit to the FDA in December. We’re seeking permission from the FDA for the Mithoefers to offer supervised MDMA experiences to therapists who are interested in possibly conducting future MDMA/PTSD studies once MAPS starts our Phase 3 multi-site studies. While bringing researchers to Charleston to observe an MDMA/PTSD session is helpful, we believe it will be even more educational to provide supervised opportunities for therapists to receive MDMA in a therapeutic context and also to practice sitting for someone else who is taking MDMA in a therapeutic context, all while being observed and educated by Michael and Annie Mithoefer.
maps.org

Пионер психоделических исследований Стэн Гроф получает престижную награду Vision 97 от бывшего президета Чешской Республики Вацлава Гавела.
Вацлав Гавел и его жена Дагмар основали свой фонд десять лет назад. Помимо распределения средств на культурные и социальные мероприятия, их фонд направлен на долговременную поддержку и организацию проектов и программ, нацеленных на будущее, имеющих новаторские идеи, ломающих традиции и усиливающих те пути развития науки и культуры, которые в наше время почти не поддерживаются большинством людей или пока не понятны большинству, но последствия которых могут существенно повлиять на будущее. Среди ранее награждённых - нейрохирург и автор "голографической модели мозга" Карл Прибрам, писатель и учёный-философ Умберто Эко, психолог, автор "Стэнфордского тюремного эксперимента" [помните немецкий фильм "Эксперимент"?:)], Филипп Зимбардо
источник - MAPS.org

Psychedelic Research Pioneer Stan Grof Receives Prestigious Havel Award
On October 5, the Board of Consultants of the Foundation of Dagmar and Vaclav Havel in Prague, Czech Republic, granted its prestigious award, Vision 97, for the year 2007 to psychiatrist, consciousness researcher, and psychedelic therapy pioneer Stanislav Grof, M.D. in a public ceremony. Former Czech President Vaclav Havel and his wife Dagmar launched their Foundation ten years ago. Besides distributing money for cultural and social purposes, this Foundation focuses on long-term support and organization of projects and programs that aim for the future, have pioneering features, attempt to break down conventions, and strengthen those avenues of science and culture, which at present do not enjoy support of the majority of people or are not comprehensible to them, but which with their consequences can inspire or otherwise meaningfully influence the future. Former recipients of the award include the author Umberto Eco, former US Secretary of Labor Robert Reich, neurosurgeon Karl H. Pribram, and psychologist Phillip G. Zimbardo.

Последний (осенний) выпуск MAPS Bulletin (pdf, ~6mb) называется "Special Edition: Psychedelics & Self-Discovery" и отличается от предыдущих наполнением в виде описаний личного опыта людей, а не отчётам о растущем количестве многообещающих исследований и образовательных проектов.
Из вступительного послания Рика Доблина (Rick Doblin, Ph.D., MAPS President) к этому выпуску мне хотелось бы выделить следующие строки:

... step forward our larger goal of building a society mature enough to integrate psychedelics and marijuana rather than prohibit and repress them.

И действительно, для достижения цели, не менее важным аспектом, чем проведение клинических исследований психоделиков с тем, чтобы убедить FDA (Управление по контролю за продуктами и лекарствами в США), что психоделики безопасны при разумном использовании и имеют терапевтическое применение, необходимо формировать зрелое общество, разумное и подготовленное в подавляющем большинстве своём; общество, которое как минимум разделяет понятия "наркотики" и "психоделики"; общество, до которого донесли и оно уже впитало в себя осознание потенциала психоделиков и их возможность улучшить качество жизни каждого человека (а значит и всего общества и окружающего мира в целом). Для этого общество должно быть осведомлено о текущих исследованиях, о сопутствующих препятствиях и их преодолении, о том, что сейчас рельно происходит в мире в этой сфере науки. И эта информация должна быть доступна не только англоговорящему населению нашей планеты, но и жителям любой страны. Для того, чтобы люди имели возможность воспринимать психоделики серьёзно, каждой группе людей, говорящей на одном языке должен быть доступен ресурс, освещающий деятельность организации MAPS.org. Насколько я знаю, сейчас нет ни одного русскоязычного сайта (ИМХО), серьёзного, авторитетного и внушающего доверия людям (в первую очередь противникам и скептикам), которые хотели бы знать, что сейчас происходит...
Мне бы хотелось так же обратить внимание на опыт одного человека, этот репорт представлен первым в последнем выпуске MAPS Bulletin.
( I had been asleep for 47 years believing that the way I saw things was pretty much the way they actually were... )

Great news. It is possible to fight the DEA and win!
( Supreme Court OKs Hallucinogenic Tea )

это сообщение из мейл-листа maps.org

From the BBC's 'A-Z of Drugs':

LSD stands for Lysergic Acid Diethylamide, a powerful hallucinogenic
drug that is derived from a fungus found growing on rye and other
wild grasses. In 1943, after accidentally swallowing some of this
chemical, a US scientist documented the first LSD 'trip'. Since then,
the US Army investigated its use as an agent capable of disabling
enemy forces, and it became a symbol of counterculture for the hippy
movement of the 1960s

On the occasion of Dr. Hofmann's centenary, I feel it would be
appropriate for this information to be corrected. I shall be writing
to those responsible for this page - crime@bbc.co.uk - and would
invite others to do the same. It would also be nice if a link to the
Hofmann Foundation were included in their page!

posted by Francis Jervis @ MAPS_Forum@maps.org, a member service of the Multidisciplinary Association for Psychedelic Studies
To subscribe, email maps_forum-subscribe@maps.org or visit http://www.maps.org/mailman/listinfo/maps_forum.